Ipratropium Bromide

CHEMBL2134724 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
412.4 g/mol
LogP
Phase
4

This bromide salt of ipratropium is the standard inhaled anticholinergic bronchodilator used for the maintenance treatment of COPD and acute management of asthma. It blocks muscarinic acetylcholine receptors in the lungs to relax airway smooth muscle and reduce secretions. It is also available as a nasal spray for rhinorrhea.

น้ำหนักโมเลกุล

412.4000 g/mol

TPSA

46.50 Ų

ด้านการรักษา

กลไกการออกฤทธิ์

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-]

InChI

InChI=1S/C20H30NO3.BrH.H2O/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H;1H2/q+1;;/p-1/t16-,17+,18+,19?,21?;;

Molecular Formula

C20H30BrNO3

HBD / HBA

1 / 4

พันธะที่หมุนได้

6

อะตอมหนัก

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This bromide salt of ipratropium is the standard inhaled anticholinergic bronchodilator used for the maintenance treatment of COPD and acute management of asthma. It blocks muscarinic acetylcholine receptors in the lungs to relax airway smooth muscle and reduce secretions. It is also available as a nasal spray for rhinorrhea.

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Yes, Ipratropium Bromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2134724. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 657308. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.